Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2018. The report discloses a transaction involving the sale of American Depositary Shares (ADS) by a Person Discharging Managerial Responsibilities (PDMR) to satisfy tax liabilities following the vesting of deferred bonus awards.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of ADSs to meet tax liabilities |
| Instrument | GlaxoSmithKline plc ADSs (ISIN: US37733W1053) |
| Total Volume | 6,000 ADSs |
| Transaction Price | $37.4803 per ADS |
| Transaction Date | February 16, 2018 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing reports a change in the beneficial interest of Mr. D E Troy (SVP & General Counsel). The sale consisted of 3,480 Deferred Bonus ADSs and 2,520 Matching Award ADSs. This transaction was executed to cover tax obligations arising from awards granted in 2015 under the 2009 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine regulatory notification of a PDMR transaction.
Key Facts for Investor Verification
- Verify the total number of shares sold (6,000) and the execution price ($37.4803) against market data for February 16, 2018.
- Confirm the identity of the seller as Mr. D E Troy, SVP & General Counsel.
- Note that the sale was mandatory to meet tax liabilities and not a discretionary reduction in holdings.
- Understand that this filing does not reflect the company's overall financial performance for the period.